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JEFFERSON INSTITUTE for BIOPROCESSING:
Advancing Biologics R&D

A JIB employee sets up a 2 L bench scale
bioreactor for CHO cell culture.
BELOW: JIB is the kind of facility you see in
a manufacturing setting—and it is unique
among academic institutions.

JIB will help advance

research

and development of biologics,
supporting both academia
and industry.
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BIOLOGICS REPRESENT ABOUT 40 PERCENT OF DRUGS IN THE
therapeutics development pipeline, and currently
account for more than $200 billion in annual global
revenue. It is an area primed for extraordinary
growth. But research and development by
pharmaceutical companies and manufacturers—
and academic research centers—are limited by
the lack of trained professionals in this field.
To meet these critical workforce needs, Jefferson
established Jefferson Institute for Bioprocessing
(JIB). It is the first—and only—specialized education
and training institute for biopharmaceutical
processing in North America that combines
commercial single-use processing equipment with
a curriculum created in collaboration with the
Ireland-based National Institute for Bioprocessing
Research and Training (a joint effort of University
College Dublin, Trinity College Dublin, Dublin City
University and the Institute of Technology, Sligo).
JIB—which opened its 25,000 square foot training
and education facility in May 2019—provides training
to industry professionals through workshops and
certificate programs and hands-on education of

new bioprocessing engineers at the undergraduate
and graduate levels. “This is the kind of facility
you see in a manufacturing setting,” says Parviz
Shamlou, PhD, JIB’s executive director. “It is, we
believe, unique among academic institutions.”

Different Manufacturing Process
Means Challenges
The growth of biologics represents a major industry
shift from traditional chemical synthesis techniques.
Biologic pharmaceuticals are manufactured in a living
system, such as a microorganism, plant or animal
cell, often using recombinant DNA technology.
However, with a complex manufacturing process
and lengthier regulatory approval process compared
to traditional small-molecule drugs, biologics remain
challenging to produce.
“Biomanufacturing is going through an unprecedented
period of innovation in new products and growth in
legacy therapeutics,” says Dr. Shamlou. “JIB will help
advance research and development of biologics,
supporting both academia and industry.” 
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